Grifols Sees Annual Savings of $230 Million After 2015

Grifols SA expects to generate annual synergies of $230 million beyond 2015 after its merger with Talecris Biotherapeutics Holdings Corp, the company said in

a presentation filed to regulators today.

Grifols, which holds an investor’s day in Barcelona Oct. 17

and Oct. 18, said total capital expenditure from 2011 to 2015 will be $964 million, while integration costs will be $70 million to 2014, lower than the initial estimate, the company said.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE